(146) N-[2-chloro-4-({7-[2-(1H-1-imidazolyl)-ethoxy]-6-methoxy-4-quinolyl}oxy)phenyl]-N′-propylurea

(148) N-[2-chloro-4-({6-methoxy-7-[2-(4-methyl-piperazino)ethoxy]-4-quinolyl}oxy)phenyl]-N′-propylurea.

A2

Please replace the paragraph beginning on page 16 at lines 4, 12 and 24 with the following rewritten paragraphs respectively:

A3

(160) N-[2-Chloro-4-({7-[4-(1H-1-imidazolyl)-butoxy]-6-methoxy-4-quinolyl}oxy)phenyl]-N′-propylurea

A4

(164) N-[2-chloro-4-({6-methoxy-7-[3-(4-methyl-piperazino)propoxy]-4-quinazolinyl}oxy)phenyl]-N′-(2,4-difluorophenyl)urea

A5

(170) N-[2-chloro-4-({6-methoxy-7-[2-(1H-1,2,3-triazol-l-yl)ethoxy]-4-quinolyl}oxy)phenyl]-N′-(2,4-difluorophenyl)urea.

IN THE CLAIMS:

In accordance with 37 CFR §1.121, please substitute for original claims 21-25, 28-32, 35-39, 42-46, 47-48, and 50-52 the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Versions With Markings to Show Changes Made."

A6

21. (Amended) The compound according to claim 19, wherein R^{31} represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C_{1-4} alkyl optionally substituted by hydroxyl, or group R^{14}-(S)m- wherein R^{14} represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C_{1-4} alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero); and p is an integer of 1 to 4.

22. (Amended) The compound according to claim 19, wherein p is 1.

23. (Amended) The compound according to claim 19, wherein R^{31} represents group R^{14}-(S)m- wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero).

A6

24. (Amended) The compound according to claim 19, wherein R^{31} represents group R^{14}-(S)m- wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.

25. (Amended) The compound according to claim 23, wherein R^{14} represents optionally substituted pyridyl.

28. (Amended) The compound according to claim 26, wherein R^{31} represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C_{1-4} alkyl optionally substituted by hydroxyl, or group R^{14}-(S)m- wherein R^{14} represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C_{1-4} alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero); and p is an integer of 1 to 4.

29. (Amended) The compound according to claim 26, wherein p is 1.

A7

30. (Amended) The compound according to claim 26, wherein R^{31} represents group R^{14}-(S)m- wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero).

31. (Amended) The compound according to claim 26, wherein R^{31} represents group R^{14}-(S)m- wherein R^{14} represents an unsaturated six-membered

heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.

32. (Amended) The compound according to claim 30, wherein R^{14} represents optionally substituted pyridyl.

35. (Amended) The compound according to claim 33, wherein R^{31} represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C_{1-4} alkyl optionally substituted by hydroxyl, or group R^{14}-(S)m- wherein R^{14} represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C_{1-4} alkyl, A8 or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero); and p is an integer of 1 to 4.

36. (Amended) The compound according to claim 33, wherein p is 1.

37. (Amended) The compound according to claim 33, wherein R^{31} represents group R^{14}-(S)m- wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero).

38. (Amended) The compound according to claim 33, wherein R^{31} represents group R^{14}-(S)m- wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.

39. (Amended) The compound according to claim 37, wherein R^{14} represents optionally substituted pyridyl.

42. (Amended) The compound according to claim 40, wherein R^{31} represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C_{1-4} alkyl optionally substituted by hydroxyl, or group R^{14}-(S)m- A9 wherein R^{14} represents a saturated or unsaturated five-membered heterocyclic

group containing 1 to 4 nitrogen atoms and optionally substituted by C_{1-4} alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero); and p is an integer of 1 to 4.

43. (Amended) The compound according to claim 40, wherein p is 1.

44. (Amended) The compound according to claim 40, wherein R^{31} represents group R^{14}-(S)m- wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero).

45. (Amended) The compound according to claim 40, wherein R^{31} represents group R^{14}-(S)m- wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.

A9

46. Amended) The compound according to claim 44, wherein R^{14} represents optionally substituted pyridyl.

47. (Amended) The compound according to claim 1, which is a compound selected from the group consisting of the following compounds, or a pharmaceutically acceptable salt or solvate thereof:

(13) N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]-phenyl}-N'-propylurea;

(51) N-(2-chloro-4-{[6-methoxy-7-(2-morpholino-ethoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl) urea;

(62) N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)-oxy]phenyl}-N'-propylurea;

(76) N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)-oxy]phenyl}-N'-ethylurea;

(117) N-{2-chloro-4-[(6,7-dimethoxy-4-quinazo-linyl)oxy]phenyl}-N'-methylurea;

(119) N-(2-chloro-4-{[6-methoxy-7-(3-morpholino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-propylurea;

(135) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-propylurea; (142) N-(2-chloro-4-{[6-methoxy-7-(3-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;

(143) N-(2-chloro-4-{[6-methoxy-7-(4-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;

(144) N-(2-chloro-4-{[6-methoxy-7-(2-morpholino-ethoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;

(145) N-[2-chloro-4-({6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;

(146) N-[2-chloro-4-({7-[2-(1H-1-imidazolyl)-ethoxy]-6-methoxy-4-quinolyl}oxy)phenyl]-N'-propylurea;

(148) N-[2-chloro-4-({6-methoxy-7-{[2-(4-methyl-piperazino)ethoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;

A9

(149) N-(2-chloro-4-{[7-(2-hydroxyethoxy)-6-methoxy-4-quinolyl]oxy}phenyl)-N'-propylurea;

(151) N-(2-chloro-4-{[6-methoxy-7-(3-morpholino-propoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;

(152) N-[2-chloro-4-(6-methoxy-7-{[3-(4-methyl-piperazino)propoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;

(153) N-[2-chloro-4-(6-methoxy-7-{[3-(1*H*-1,2,3-triazol-1-yl)propoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;

(157) N-{2-chloro-4-[(7-{3-[(2-hydroxyethyl)-(methyl)amino]propoxy}-6-methoxy-4-quinolyl)oxy]-phenyl}-N'-propylurea;

(159) N-{2-chloro-4-[(6-methoxy-7-{[5-(1*H*-1,2,3-triazol-1-yl)pentyl]oxy}-4-quinolyl)oxy]phenyl}-N'-propylurea;

(160) N-[2-chloro-4-({7-[4-(1*H*-1-imidazolyl)-butoxy]-6-methoxy-4-quinolyl}oxy)phenyl]-N'-propylurea;

(162) N-(2-chloro-4-{[6-methoxy-7-(2-morpholino-ethoxy)-4-quinazolinyl]oxy}phenyl)-N'-(2,4-difluoro-phenyl)urea;

(163) N-(2-chloro-4-{[6-methoxy-7-(3-morpholino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-(2,4-difluoro-phenyl)urea;

(164) N-[2-chloro-4-({6-methoxy-7-[3-(4-methyl-piperazino)propoxy]-4-quinazolinyl}oxy)phenyl]-N'-(2,4-difluorophenyl)urea;

(165) N-{2-chloro-4-[(7-{3-[(2-hydroxyethyl)-(methyl)amino]propoxy}-6-methoxy-4-quinazolinyl)oxy]-phenyl}-N'-(2,4-difluorophenyl)urea;

(168) N-(2-chloro-4-{[6-methoxy-7-(3-morpholino-propoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl)-urea;

(169) N-(2-chloro-4-{[6-methoxy-7-(3-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl)-urea;

(170) N-[2-chloro-4-({6-methoxy-7-[2-(1*H*-1,2,3-triazol-1-yl)ethoxy]-4-quinolyl}oxy)phenyl]-N'-(2,4-difluorophenyl)urea;

A9

(184) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-methylurea;

(185) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-ethylurea; and

(186) N-(2-chloro-4-{[6-methoxy-7-(4-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl)-urea.

48. (Amended) A pharmaceutical composition comprising as active ingredient the compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof.

50. (Amended) Use of the compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a therapeutic agent for use in the treatment of a disease selected from the group consisting of tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma.

A10

51. (Amended) A method for treating a disease selected from the group consisting of tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma, comprising the step of administering an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, to mammals.

B3

A10

52. (Amended) A method for inhibiting the angiogenesis of target blood vessels, comprising the step of making the compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof in contact with vascular endothelial cells of the target blood vessels.